Business
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results
Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fi
About this update from Prestige Consumer Healthcare Inc.
[{"type":"image","alt":"Prestige Consumer Healthcare Inc.","displaySize":"","headline":null,"caption":"Prestige Consumer Healthcare Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FLwmlDskH0PHRRLgz3xb6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1b5655ca12a92f858081df51ed2ce36b","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $249.5 million in Q1; decline driven by limited eye care supply","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces agreement to acquire current eye care supplier Pillar5 Pharma","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Revising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":346,"olType":false},{"type":"text","content":"TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025.","length":183,"tagName":"p"},{"type":"text","content":"“We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross margin, and solid quarterly free cash flow. Unfortunately, these positives were offset by Clear Eyes supply constraints, which resulted in lower-than-expected shipments. As we look forward, we continue to expect planned improvements in eye care supply in the second half, further helped by this morning’s announcement to acquire Pillar5. In addition, we believe the benefits of our diverse portfolio, financial profile and free cash flow should continue to drive long-term shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.","length":732,"tagName":"p"},{"type":"text","content":"First Fiscal Quarter Ended June 30, 2025","length":40,"tagName":"p"},{"type":"text","cont...